CRL (Charles River Lab)
All Pro Portfolios with CRL
- Total Pro Portfolios with CRL:
- Buffalo Science & Technology BUFTX
- Viking Global Investors
- Buffalo Mid Cap - BUFMX
- show more
All Do-It-Yourself Portfolios with CRL
- Total Do-It-Yourself Portfolios with CRL:
- WESOLBROKE
- burkss Portfolio 1
- SUPRATRADE-QUANTUM STARDUST 8
- stewarg66 Healthcare list
- SUPRATRADE 2307070204
- Insider Purchases and Buybacks XVII
- dgc011757 Portfolio 1
- bostonstrangler Portfolio 1
- nik's healthcare portfolio
- TommieD 2
- KJMARINO's picks
- stocks4me#3
- PART 3 JPMorgan 27th Annual Healthcare Conf 1/13/09..2nd Day Reporting Companies..Nymph Take
- show more
- 26
- btown Portfolio 1
- SPSTOCK
- Target Portfolio
- stewarg66 Healthcare pics
- Panna Portfolio 1
- johnem 1a
- Old Lane, LP
- DavidFee2001 Portfolio 1
- PART 3 JPMorgan 26th Annual Healthcare Conf 1/8/08..2nd Day Reporting Companies..Nymph Take
- ginny
- Cramer's Outsourcing R&D Stock Plays
- 061408mine
- Lingo Holdings
- News For Selected Stock
- Related stories on theStreet.com
- videos related to etf's
- No videos found
- blogs related to etf's
- No blogs found
Why I Love This Stock |
|
By:lsnowberger |
Date:06 14 08 |
solid gains |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Goldman Sachs said it is upgrading Charles River (CRL) to Buy from Neutral based on attractive preclinical positioning, upcoming margin gains in 2008, and relative valuation. Price target raised $2 to $73. |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Charles River Labs (CRL) was upgraded to Buy rating from Neutral at UBS. Price target lifts to $72 from $71 and FY 2008 eps estimates hold at $2.97. |
|
Not yet rated
Rate now:
|
|
By:barrons2 |
Date:01 17 08 |
Cramer also recommended Charles River Labs (CRL) as an early stage CRO play and Parexel (PRXL) as a pure-play late stage CRO. |
|
Not yet rated
Rate now:
|
|
By:KJMarino |
Date:01 16 08 |
CRO early stage |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Charles River Labs (CRL) was downgraded to Neutral rating from Buy at UBS. Price target and FY 2008 eps estimates hold at $69 and $2.64, respectively. |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Charles River Labs (CRL) was upgraded to Buy rating from Neutral at UBS. Price target jumps to $67 from $58 and FY 2007 eps estimates upped to $2.52 from $2.50. |
|
Not yet rated
Rate now:
|
|
By:johnem |
Date:08 26 07 |
gittin older and older |
|
Not yet rated
Rate now:
|
|
By:sarah z |
Date:08 15 07 |
Charles River Labs recently announced a $100 million dollar buyback which adds to its prior plan. |
|
Not yet rated
Rate now:
|
|
By:Pro |
Date:11 30 -1 |
Downgraded by Banc of America Sec from Buy to Neutral |
|
Not yet rated
Rate now:
|
|
Why I Hate This Stock |
|
| Comments not available |